Why Diversity Should Still Matter Shorts

1. Why Representation Is More Than A Diversity Checkbox 7/23/2026

   Kemi Williams explains the distinction between diversity and representation, using the donanemab Alzheimer’s trial as an example of how underrepresentation can create real clinical and labeling consequences.

2. This Isn't Just A Compliance Exercise 7/23/2026

   Natalie Monegro argues that representative enrollment is a scientific imperative, not merely a compliance exercise, and explains why sponsors need to show how trial data will be used to support real-world treatment and commercialization.

3. Representative Trials Must Look Beyond Race And Ethnicity 7/23/2026

   Kemi Williams broadens the definition of representation to include geography, literacy, age, comorbidities, sexual orientation, gender identity, and other factors, emphasizing that trials must reflect the populations most affected by a disease.

4. Trial Design Choices Determine Who Gets Access 7/23/2026

   When asked what advice they have for sponsors, sites, or regulators, Natalie Monegro talks about the issues we can control from the onset of the trial that affect inclusiveness.

5. Patients Should Shape Trials Before Protocols Are Finalized 7/23/2026

   Leida Bowen explains how patient councils and early community input can inform protocol design, reduce burden, and ensure trials reflect patient needs before study execution begins.

6. Education Is Essential To Representative Enrollment 7/23/2026

   According to Leida Bowen, the biggest challenge with inclusive trials is often education, helping colleagues and stakeholders better understand patient disparities and experiences so they can avoid unintentionally creating barriers to participation.